-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Down 32.9% in August
Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Down 32.9% in August
Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating) was the target of a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 396,100 shares, a drop of 32.9% from the August 15th total of 590,700 shares. Currently, 2.5% of the company's shares are sold short. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is currently 0.4 days.
Hedge Funds Weigh In On Sunshine Biopharma
Institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new position in Sunshine Biopharma in the 1st quarter worth about $31,000. Virtu Financial LLC purchased a new position in Sunshine Biopharma in the 1st quarter worth about $34,000. Bank of Montreal Can purchased a new position in Sunshine Biopharma in the 2nd quarter worth about $40,000. Finally, Empery Asset Management LP purchased a new position in Sunshine Biopharma in the 1st quarter worth about $1,104,000. Hedge funds and other institutional investors own 3.90% of the company's stock.
Get Sunshine Biopharma alerts:Sunshine Biopharma Price Performance
Shares of SBFM opened at $1.04 on Wednesday. The business's 50-day moving average price is $1.14 and its 200 day moving average price is $1.98. Sunshine Biopharma has a 1-year low of $1.01 and a 1-year high of $29.80.
About Sunshine Biopharma
(Get Rating)Sunshine Biopharma, Inc, a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound.
See Also
- Get a free copy of the StockNews.com research report on Sunshine Biopharma (SBFM)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Rating) was the target of a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 396,100 shares, a drop of 32.9% from the August 15th total of 590,700 shares. Currently, 2.5% of the company's shares are sold short. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is currently 0.4 days.
陽光生物醫藥股份有限公司(納斯達克代碼:SBFM-GET Rating)是空頭股數8月份大幅下跌的目標。截至8月31日,空頭股數共有39.61萬股,較8月15日的59.07萬股下降了32.9%。目前,該公司2.5%的股票被賣空。根據日均成交量1,100,000股計算,目前天數與回補比率為0.4天。
Hedge Funds Weigh In On Sunshine Biopharma
對衝基金參與陽光生物醫藥
Institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new position in Sunshine Biopharma in the 1st quarter worth about $31,000. Virtu Financial LLC purchased a new position in Sunshine Biopharma in the 1st quarter worth about $34,000. Bank of Montreal Can purchased a new position in Sunshine Biopharma in the 2nd quarter worth about $40,000. Finally, Empery Asset Management LP purchased a new position in Sunshine Biopharma in the 1st quarter worth about $1,104,000. Hedge funds and other institutional investors own 3.90% of the company's stock.
機構投資者最近買賣了該股的股票。簡街集團(Jane Street Group LLC)在第一季度購買了陽光生物醫藥的一個新頭寸,價值約3.1萬美元。Virtu Financial LLC在第一季度購買了陽光生物醫藥的新頭寸,價值約3.4萬美元。蒙特利爾銀行可以在第二季度購買陽光生物醫藥的一個新頭寸,價值約4萬美元。最後,Empery Asset Management LP在第一季度購買了陽光生物醫藥的一個新頭寸,價值約1,104,000美元。對衝基金和其他機構投資者持有該公司3.90%的股份。
Sunshine Biopharma Price Performance
陽光生物醫藥價格表現
Shares of SBFM opened at $1.04 on Wednesday. The business's 50-day moving average price is $1.14 and its 200 day moving average price is $1.98. Sunshine Biopharma has a 1-year low of $1.01 and a 1-year high of $29.80.
週三,SBFM的股價開盤報1.04美元。該業務的50日移動均線價格為1.14美元,200日移動均線價格為1.98美元。陽光生物醫藥的一年低點為1.01美元,一年高位為29.80美元。
About Sunshine Biopharma
關於陽光生物醫藥
Sunshine Biopharma, Inc, a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound.
陽光生物醫藥公司是一家制藥和營養補充劑公司,專注於抗癌藥物的研發。該公司正在開發Adva-27A,一種鬼臼毒素的寶石二氟碳糖苷衍生物,用於治療白血病、淋巴瘤、睾丸、肺癌、腦、前列腺癌、膀胱癌、結腸癌、卵巢、肝癌和其他形式的癌症,以及殺死多藥耐藥癌細胞,包括胰腺癌、乳腺癌、小細胞肺癌和子宮肉瘤細胞;以及SBFM-PL4,一種抗冠狀病毒治療化合物。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Sunshine Biopharma (SBFM)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 免費獲取StockNews.com關於陽光生物醫學的研究報告(SBFM)
- 這三份報告將告訴我們許多關於當前經濟的情況。
- 下面的五個是不是打得太高了?
- 這就是現在對標準普爾500指數的預期
- 關於甲骨文的FQ1報告,你需要知道的兩件事
- 波動市場的三隻價值股
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《陽光生物報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對陽光生物醫藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧